# A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

> **NCT03827668** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-06650833 alone
- **DRUG:** PF-06651600 alone
- **DRUG:** PF-06650833 together with PF-06651600

## Key facts

- **NCT ID:** NCT03827668
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-07
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-04-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827668, "A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03827668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*